camrelizumabgemcitabinecisplatinhigh risk nasopharyngeal carcinoma
…se events (grade 3 or 4) occurred in 19 patients (10.2%) in the camrelizumab group.Conclusion The addition of camrelizumab to concurrent che…
6articles mentioning drugs
29drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Camrelizumab ×
Camrelizumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Camrelizumab
6 articles · page 1 of 1camrelizumaboxaliplatinapatinibcapecitabinecamreCAPOX
…amre+apa), CAPOX alone, and camrelizumab plus CAPOX followed by camrelizumab (camre+CAPOX followed by camre) as initial treatment for gastri…
camrelizumabFujian Medical University Union HospitalChinese Academy of Medical SciencesPeking Union Medical CollegeneoCRTSichuan Cancer Hospital and Institute
…group, patients achieving a clinical complete response (cCR) to camrelizumab combined with neoCRT will undergo active surveillance, while th…
nivolumabpembrolizumab
…city, with G3/4 events reported in 22% compared with 14% in the nivolumab monotherapy arm. An update presented at the European Society of…
camrelizumabNSCLCchemotherapyNCT06241807
…prognostic biomarkers in resectable NSCLC receiving neoadjuvant camrelizumab plus chemotherapy.Trial registration number NCT06241807.…
paclitaxelcamrelizumabcisplatinChiCTR2000040034chemotherapychemoimmunotherapyESCC
…its combination with PD-1 blockade (camrelizumab, albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin, Cam+nab-TP/TP; n=41), f…